New Zealand markets open in 8 hours 10 minutes

Alphamab Oncology (9966.HK)

HKSE - HKSE Delayed price. Currency in HKD
Add to watchlist
2.570-0.040 (-1.53%)
At close: 04:08PM HKT
Currency in HKD

Valuation measures4

Market cap (intra-day) 2.52B
Enterprise value 1.25B
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)10.42
Price/book (mrq)1.37
Enterprise value/revenue 5.22
Enterprise value/EBITDA -52.96

Trading information

Stock price history

Beta (5Y monthly) 0.27
52-week change 3-65.70%
S&P500 52-week change 324.71%
52-week high 313.460
52-week low 32.000
50-day moving average 34.217
200-day moving average 36.311

Share statistics

Avg vol (3-month) 37.56M
Avg vol (10-day) 318.99M
Shares outstanding 5964.92M
Implied shares outstanding 6990.8M
Float 8417.06M
% held by insiders 150.79%
% held by institutions 113.35%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Currency in CNY.

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin -96.26%
Operating margin (ttm)-241.41%

Management effectiveness

Return on assets (ttm)-9.50%
Return on equity (ttm)-13.04%

Income statement

Revenue (ttm)218.77M
Revenue per share (ttm)0.23
Quarterly revenue growth (yoy)-27.30%
Gross profit (ttm)N/A
EBITDA -267.54M
Net income avi to common (ttm)-210.59M
Diluted EPS (ttm)-0.240
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)1.41B
Total cash per share (mrq)1.5
Total debt (mrq)257.08M
Total debt/equity (mrq)15.38%
Current ratio (mrq)5.84
Book value per share (mrq)1.78

Cash flow statement

Operating cash flow (ttm)-202.84M
Levered free cash flow (ttm)-179.06M